📰 Our Investment Director, @russmould1, comments on drug giant AstraZeneca and its smaller US rival, Gilead, holding merger discussions in this @MailOnline article &gt;&gt;&gt; https://t.co/reQaGbZYX6
 
#Investors #COVID19 #Stocks